CA-GILEAD-SCIENCES
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for the company’s New Drug Application (NDA) for an investigational, fixed-dose combination of bictegravir (50mg) (BIC), a novel investigational integrase strand transfer inhibitor (INSTI), and emtricitabine/tenofovir alafenamide (200/25mg) (FTC/TAF), a dual-NRTI backbone, for the treatment of HIV-1 infection. Gilead filed the NDA for BIC/FTC/TAF with a Priority Review voucher on June 12, 2017, and FDA has set a target action date under the Prescription Drug User Fee Act (PDUFA) of February 12, 2018.
The NDA is supported by data from four Phase 3 studies that evaluated the fixed-dose combination among treatment-naïve patients and among virologically suppressed patients. A marketing application for BIC/FTC/TAF is also under review in the European Union, and was validated by the European Medicines Agency (EMA) in July. Bictegravir in combination with FTC/TAF as a single tablet regimen is an investigational treatment that has not been determined to be safe or efficacious and is not approved anywhere globally.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.
For nearly 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention, testing and linkage to care, and cure research. Today, it’s estimated that more than 10 million people living with HIV globally receive antiretroviral therapy provided by Gilead or one of the company’s manufacturing partners.
Forward-Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility that FDA and other regulatory authorities may not approve BIC/FTC/TAF in the currently anticipated timelines or at all, and any marketing approvals, if granted, may have significant limitations on their use. As a result, BIC/FTC/TAF may never be successfully commercialized. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170810006058/en/
Contact:
Gilead Sciences, Inc.
Sung Lee, 650-524-7792 (Investors)
Kelsey
Grossman, 650-378-2103 (Media)
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yokogawa Collaborates with Shell on Robotics and AI Technology for Plant Maintenance18.6.2025 08:00:00 CEST | Press release
- Streamlining operations and reducing risk in asset integrity management – Yokogawa Electric Corporation (TOKYO: 6841) announces that it has formalized a long-term agreement with Shell Global Solutions International B.V. (“Shell”) to integrate and further develop technologies for utilizing robots and drones in plant monitoring and maintenance. Under the agreement, Yokogawa will add an advanced machine vision tool called Operator Round by Exception (ORE), developed by Shell, into its own OpreX™ Robot Management Core. The enhanced software service will be made available by Yokogawa to customers in the energy, chemicals, and other industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617976629/en/ OpreX Robot Management Core ORE is a digital solution that uses machine vision and AI analytics to enable robots to autonomously perform a number of tasks in the operator round process, such as reading gauges and checking for
Ververica Announces Partnership with Aiven - Empowering Leading Enterprises to Create Value from their Data in Real-Time18.6.2025 08:00:00 CEST | Press release
Ververica, the original creators of Apache Flink® and a leader in stream processing technology, today announced a new partnership with Aiven, the AI-ready open source cloud data platform. This partnership enables Aiven to provide Ververica’s Unified Streaming Data Platform to their customers, expanding access to enterprise-grade streaming data capabilities for data-driven businesses around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617806011/en/ Ververica Announces Partnership with Aiven - Empowering Leading Enterprises to Create Value from their Data in Real-Time Under the partnership, Aiven customers can now unlock enterprise-grade stream processing with Ververica’s powerful platform — allowing them to make decisions and take actions at speed with data from any source — plus expert support from the original creators of Apache Flink. “This partnership is about removing friction and delivering real business
ICD 2025: New data demonstrate Nemluvio®’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years18.6.2025 07:00:00 CEST | Press release
An interim analysis of the OLYMPIA long-term extension study to be presented as a late-breaking abstract at the XIV International Congress of Dermatology (ICD) found that Nemluvio was well tolerated and associated with sustained and clinically meaningful improvements in the key signs and symptoms of prurigo nodularis, including both skin lesions and itch, up to two years1 Results build on data from OLYMPIA – the largest completed pivotal clinical program in prurigo nodularis and the only one assessing long-term safety and efficacy in prurigo nodularis1-3 This follows the presentation of data from the ARCADIA long-term extension study at the Revolutionizing Atopic Dermatitis (RAD) Conference earlier this month, which showed Nemluvio is well tolerated with sustained and increased improvements in efficacy outcomes in atopic dermatitis patients up to two years4 Galderma (SIX: GALD) today announced data from a new interim analysis of a study investigating the long-term safety and efficacy o
LabPMM® Receives New York State Approval for the NPM1 MRD Assay - Informing Therapy and Accelerating Targeted Trials18.6.2025 06:30:00 CEST | Press release
Invivoscribe is happy to announce that its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine® (LabPMM) has received approval from New York State (NYS) for the NPM1 MRD Assay. This approval comes just two months after gaining NYS approval for our FLT3 ITD MRD Assay. Together these tests represent a critical tool for patients with acute myeloid leukemia (AML), clinicians and pharmaceutical companies. This new approval underscores Invivoscribe’s ongoing commitment to providing the most accurate, standardized measurable residual disease (MRD) testing solutions worldwide. The NPM1 MRD Assay is a pivotal development in the fight against AML, offering an ultra-sensitive DNA sequencing method to accurately measure trace levels of residual leukemia cells in patients with the NPM1 mutation variants. NPM1 mutations are considered an ideal target for MRD assessment because they are present in ~30% of adult AML cases,1 stable over time,2 and, if present in blood at allele
DNP to Take Controlling-Stake in Laxton18.6.2025 03:30:00 CEST | Press release
Maximizing synergies to accelerate the global expansion of biometric info-driven government authentication and security business Dai Nippon Printing Co., Ltd. (DNP, TOKYO: 7912) entered into a share transfer agreement on June 17, 2025 to acquire Cayman Islands-headquartered Rubicon SEZC. Rubicon (a holding company of “Laxton” group) is a global Identity Systems Integrator that provides ID solutions for governments, primarily in developing nations, to register and authenticate personal information. DNP plans to acquire 75% of Rubicon's shares in July and complete the procedures to make the company a Group company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250613922077/en/ Products of Laxton DNP will maximize synergies with Laxton in ID cards and card printers. By expanding to government-related business in Africa, Asia, South America, and other regions, we will further grow our authentication and security business, contr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom